knowledge -WSS

knowledge

author：entertainment 2025-09-28 06:31:43 Page View：75

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 5 takeaways from STAT's examination of Zynex Medical
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Coercive sterilizations revealed by STAT prompt outrage

Illustration:ChristineKao/STAT;Photos:AlissaAmbrose/STAT,Adobe,MichaelStarghillforSTATFederalofficia

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Vertigo drug brings hope for rare neuron disorder, Niemann

ThecerebellumofamousebrainaffectedbyNiemann-PickTypeC.EuniceKennedyShriverNationalInstituteofChildHe

knowledge

leisure time

explore

Vertigo drug brings hope for rare neuron disorder, Niemann